Abstract
Although β2-receceptor agonists are powerful bronchodilators and are at the forefront of asthma symptom relief, patients who use them frequently develop partial resistance to them. This can be a particularly serious problem during severe attacks, where high dose β2-agonist treatment is the front line therapy. Alternative bronchodilators are urgently needed. In this article we review the evidence for the bronchodilator effects of the cannabinoid CB1 receptor tetrahydrocannabinol (THC) and suggest that the mechanisms of action for these effects are sufficiently independent of the mechanisms of standard bronchodilators to warrant clinical investigation. Specifically, clinical trials testing the bronchodilator effects of THC in β2 agonist resistant asthmatic patients would show whether THC could fill the role of rescue bronchodilator in cases of β2 agonist resistance.
Keywords: Asthma, bronchodilation, β2-agonist, CB1 receptor, salbutamol, THC.
Current Drug Targets
Title:The Case for Cannabinoid CB1 Receptors as a Target for Bronchodilator Therapy for β-agonist Resistant Asthma
Volume: 19 Issue: 11
Author(s): John C. Ashton*Robert J. Hancox
Affiliation:
- Department of Pharmacology & Toxicology, Otago School of Biomedical Sciences, University of Otago, Dunedin,New Zealand
Keywords: Asthma, bronchodilation, β2-agonist, CB1 receptor, salbutamol, THC.
Abstract: Although β2-receceptor agonists are powerful bronchodilators and are at the forefront of asthma symptom relief, patients who use them frequently develop partial resistance to them. This can be a particularly serious problem during severe attacks, where high dose β2-agonist treatment is the front line therapy. Alternative bronchodilators are urgently needed. In this article we review the evidence for the bronchodilator effects of the cannabinoid CB1 receptor tetrahydrocannabinol (THC) and suggest that the mechanisms of action for these effects are sufficiently independent of the mechanisms of standard bronchodilators to warrant clinical investigation. Specifically, clinical trials testing the bronchodilator effects of THC in β2 agonist resistant asthmatic patients would show whether THC could fill the role of rescue bronchodilator in cases of β2 agonist resistance.
Export Options
About this article
Cite this article as:
Ashton C. John *, Hancox J. Robert, The Case for Cannabinoid CB1 Receptors as a Target for Bronchodilator Therapy for β-agonist Resistant Asthma, Current Drug Targets 2018; 19 (11) . https://dx.doi.org/10.2174/1389450118666170615101220
DOI https://dx.doi.org/10.2174/1389450118666170615101220 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adrenal Insufficiency Caused by Locally Applied Glucocorticoids-Myth or Fact?
Current Medicinal Chemistry Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics Peripheral TRPV1 Receptors As Targets for Drug Development: New Molecules and Mechanisms
Current Pharmaceutical Design Carnosine and Lung Disease
Current Medicinal Chemistry Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Aerosol Drug Administration with Helium-Oxygen (Heliox) Mixtures: An Overview
Current Respiratory Medicine Reviews Immunodominant IgE Epitopes of Der p 5 Allergen
Protein & Peptide Letters The Voyage of Natural Chalcone: Isoliquiritigenin
Current Bioactive Compounds Metabolic Changes in Autoimmune Diseases
Current Drug Discovery Technologies Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews The Antioxidant Response Element and Oxidative Stress Modifiers in Airway Diseases
Current Molecular Medicine Severe Preeclampsia
Current Women`s Health Reviews A Review of Phytochemical and Pharmacological Studies of Inula Species
Current Bioactive Compounds The Prevalence of Rhinosinusitis Disease among Asthma Patients in Saudi Arabia
Current Respiratory Medicine Reviews Optimal Sedation for the Ventilation of Critically Ill Patients
Current Respiratory Medicine Reviews Dietary Small Molecules and Large-Scale Gene Expression Studies: An Experimental Approach for Understanding their Beneficial Effects on the Development of Malignant and Non-Malignant Proliferative Diseases
Current Medicinal Chemistry Molecular Modelling Simulations and Inhibitory Effects of Naturally Derived Flavonoids Targeting Platelet-Activating Factor Receptor (PAFR)
Letters in Drug Design & Discovery Prevalence of Tooth Wear in Primary Dentition in School Children of Abu Dhabi, UAE
Applied Clinical Research, Clinical Trials and Regulatory Affairs Editorial [ Hot Topic: State of the Science: Pediatric Asthma (Guest Editors: Barbara Velsor-Friedrich and Arlene Butz)]
Current Pediatric Reviews C5a, a Therapeutic Target in Sepsis
Recent Patents on Anti-Infective Drug Discovery